This is the category page. Below are all of the research programs that are associated with it
Kidney Transplant:
BELATACEPT FOR RENAL ALLOGRAFT RECIPIENTS: A COMPASSIONATE USE PROGRAM
(2_20090908_118)
This study drug is for participants who have undergone kidney transplant, who are unable to tolerate or have contraindications to CNIs and/or m-TOR inhibitors and are unable to establish an adequate immunosuppression regimen or at immediate risk of losing the transplanted kidney due to nephrotoxicity and have no other options for immunosuppression. The study is a compassionate use program.
Kidney Tumor in Children -
COG #ANEN0532: TREATMENT FOR VERY LOW AND STANDARD RISK FAVORABLE HISTOLOGY WILMS TUMOR
(1_20080408_118)
All participants on this study must have been enrolled on AREN03B2. There are three arms to this study. Participants will receive nephrectomy and observation only; or chemotherapy alone; or chemotherapy with radiation therapy. Most participants will have had total resection of the kidney and tumor. Patients with unresectable or incompletely resected tumors will receive chemotherapy and be re-evaluated following 2 cycles (approximately 6 weeks). If the tumor is determined to be resectable, further surgery will be performed.
